Back to Search
Start Over
Biodistribution of Antibody-MS2 Viral Capsid Conjugates in Breast Cancer Models
- Source :
- Molecular pharmaceutics. 13(11)
- Publication Year :
- 2016
-
Abstract
- A variety of nanoscale scaffolds, including virus-like particles (VLPs), are being developed for biomedical applications; however, little information is available about their in vivo behavior. Targeted nanoparticles are particularly valuable as diagnostic and therapeutic carriers because they can increase the signal-to-background ratio of imaging agents, improve the efficacy of drugs, and reduce adverse effects by concentrating the therapeutic molecule in the region of interest. The genome-free capsid of bacteriophage MS2 has several features that make it well-suited for use in delivery applications, such as facile production and modification, the ability to display multiple copies of targeting ligands, and the capacity to deliver large payloads. Anti-EGFR antibodies were conjugated to MS2 capsids to construct nanoparticles targeted toward receptors overexpressed on breast cancer cells. The MS2 agents showed good stability in physiological conditions up to 2 days and specific binding to the targeted receptors in in vitro experiments. Capsids radiolabeled with
- Subjects :
- Biodistribution
viruses
Pharmaceutical Science
Mice, Nude
Breast Neoplasms
02 engineering and technology
010402 general chemistry
01 natural sciences
Antibodies
Mice
Breast cancer
Capsid
In vivo
Positron Emission Tomography Computed Tomography
Drug Discovery
Bacteriophage MS2
medicine
Animals
Humans
Receptor
Levivirus
Mice, Inbred BALB C
Bioconjugation
Microscopy, Confocal
biology
Chemistry
021001 nanoscience & nanotechnology
medicine.disease
biology.organism_classification
Flow Cytometry
Virology
0104 chemical sciences
biology.protein
Cancer research
MCF-7 Cells
Molecular Medicine
Nanoparticles
Capsid Proteins
Female
Antibody
0210 nano-technology
Subjects
Details
- ISSN :
- 15438392
- Volume :
- 13
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Molecular pharmaceutics
- Accession number :
- edsair.doi.dedup.....40c597fa202b53c42772f66b69638679